Familial dilated cardiomyopathy brought on by a novel variant

Immunological and genetic kinetics from analysis to scientific development in continual lymphocytic leukemia
Background: Mechanisms driving the development of continual lymphocytic leukemia (CLL) from its early phases are usually not absolutely understood. The acquisition of molecular adjustments on the time of development has been noticed in a small fraction of sufferers, suggesting that CLL development isn’t primarily pushed by dynamic clonal evolution.

So as to make clear mechanisms that result in CLL development, we investigated longitudinal adjustments in each the genetic and immunological eventualities.

Strategies: We carried out genetic and immunological longitudinal evaluation utilizing paired main samples from untreated CLL sufferers that underwent scientific development (sampling at analysis and development) and from sufferers with steady illness (sampling at analysis and at long-term asymptomatic follow-up).

Outcomes: Molecular evaluation confirmed restricted and non-recurrent molecular adjustments at development, indicating that clonal evolution isn’t the principle driver of scientific development.

Our evaluation of the immune kinetics discovered an more and more dysfunctional CD8+ T cell compartment in progressing sufferers that was not noticed in these sufferers that remained asymptomatic.

 

Particularly, terminally exhausted effector CD8+ T cells (T-betdim/-EomeshelloPD1hello) accrued, whereas the the co-expression of inhibitory receptors (PD1, CD244 and CD160) elevated, together with an altered gene expression profile in T cells solely in these sufferers that progressed. As well as, malignant cells from sufferers at scientific development confirmed enhanced capability to induce exhaustion-related markers in CD8+ T cells ex vivo primarily by way of a mechanism depending on soluble components together with IL-10.

Conclusions: Altogether, we display that the interplay with the immune microenvironment performs a key position in scientific development in CLL, thereby offering a rationale for using early immunotherapeutic intervention.
rhodococcus
rhodococcus

Cat IgG Fab2-Biotin conjugate (non-immune, isotype control) purified

20002-4-B 0.1 mg
EUR 225

Cat IgG Fab2-FITC conjugate (non-immune, isotype control) purified

20002-4-F 0.1 mg
EUR 225

Cat IgG Fab2-HRP conjugate (non-immune, isotype control) purified

20002-4-HP 0.1 mg
EUR 225

Cat IgG Fab2, unlabeled (non-immune, isotype control) purified

20002-4-UL 0.1 mg
EUR 164

Cat IgM-Biotin conjugate (non-immune, isotype control) purified

20002-5-B 0.1 mg
EUR 225

Cat IgM, unlabeled (non-immune, isotype control) purified

20002-5-UL 0.1 mg
EUR 164

FluoroQuest™ Anti-fading Kit II *Optimized for Plate Imaging*

20003 1 kit
EUR 132
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 12352200

Hamster IgG, purified (Syrian, isotype control)

20003-1 1 mg
EUR 141

Hamster IgG-Biotin conjugate, isotype control (Syrian)

20003-1-B 100 test
EUR 164

Hamster IgG-Cy5 conjugate, isotype control (Syrian)

20003-1-Cy5 50 tests
EUR 225

Hamster IgG-FITC conjugate, isotype control (Syrian)

20003-1-F 100 tests
EUR 164

Hamster IgG-HRP conjugate, isotype control (Syrian)

20003-1-HP 100 tests
EUR 164

Hamster IgG-R-PE-Cy5.5 conjugate, isotype control (Syrian)

20003-1-PC5 50 tests
EUR 250

Hamster IgG-R-PE conjugate, isotype control (Syrian)

20003-1-PE 50 tests
EUR 225

Hamster IgG, purified (Armenian, Isotype control)

20003-1AH 1 mg
EUR 263

Hamster (Syrian, non-immune) Serum IgM, purified (Syrian)

20003-2-1 0.5 mg
EUR 225

FluoroQuest™ Mounting Medium with DAPI

20004 50 mL
EUR 132
  • R-phrase: R20, R21, R68
  • H-Phrase: H303, H313, H340
  • Symbol for dangerous compounds: T
  • UNSPEC Code: 12352200

G. Pig IgG, purified (non-immune, serum, Isotype control)

20004-1 1 mg
EUR 141

G. Pig IgM, purified (non-immune, serum, Isotype control)

20004-2-1 0.5 mg
EUR 225

G. Pig IgG Fc-Biotin conjugate (isotype control, non-immune) purified

20004-3-B 0.1 mg
EUR 225

G. Pig IgG Fc-FITC conjugate (isotype control, non-immune) purified

20004-3-F 0.1 mg
EUR 225

G. Pig IgG Fc-HRP conjugate (isotype control, non-immune) purified

20004-3-HP 0.1 mg
EUR 225

G. Pig IgG Fc unlabeled (isotype control, non-immune) purified

20004-3-UL 0.5 mg
EUR 202

G. Pig IgA, purified (non-immune, serum, Isotype control)

20004-5-1 100 ug
EUR 347

G. Pig IgG-Biotin conjugate (isotype control)

20004-B 100 ug
EUR 202

G. Pig IgG-FITC conjugate (isotype control)

20004-F 100 ug
EUR 202

G. Pig IgG-HRP conjugate (isotype control)

20004-HP 100 ug
EUR 202

Rat IgG, purified (Whole, non-immune) (isotype control)

20005-1 1 mg
EUR 141

Rat IgG purified (isotype control)

20005-1-200 0.5 ml
EUR 103

Rat IgG Fab fragment, purified (isotype control)

20005-1-FAB 1 mg
EUR 164

Rat IgG F(ab')2 fragment, purified (isotype control)

20005-1-FAB2 1 mg
EUR 202

Rat IgG (Fc) fragment, purified (isotype control)

20005-1-FC 0.5 mg
EUR 250

Rat IgG (Fc)-Biotin Conjuagte (isotype control), purified

20005-1-FC-B 0.1 mg
EUR 225

Rat IgG (Fc)-FITC Conjuagte (isotype control), purified

20005-1-FC-F 0.1 mg
EUR 225

Rat IgG (Fc)-HRP Conjuagte (isotype control), purified

20005-1-FC-HP 0.1 mg
EUR 225

Rat IgG, purified (Whole, non-immune) (isotype control)

20005-10 10 mg
EUR 408

Rat IgG1 cunonjugated (isotype control)

20005-11 100 ug
EUR 164

Rat IgG1-Biotin conjugate (isotype control)

20005-11-B 100 ug
EUR 202

Rat IgG1-FITC conjugate (isotype control)

20005-11-F 100 ug
EUR 225

Rat IgG1-HRP conjugate (isotype control)

20005-11-HP 100 ug
EUR 202

Rat IgG1-R-PE-Cy5.5 conjugate (isotype control)

20005-11-PC5 25 tests
EUR 202

Rat IgG1-R-PE conjugate (isotype control)

20005-11-PE 25 tests
EUR 202

Rat IgG2a unconjugated (isotype control)

20005-12 100 ug
EUR 164

Rat IgG2a-APC conjugate (isotype control)

20005-12-APC 25 tests
EUR 202

Rat IgG2a-Biotin conjugate (isotype control)

20005-12-B 100 ug
EUR 202

Rat IgG2a-FITC conjugate (isotype control)

20005-12-F 100 ug
EUR 225

Rat IgG2a-HRP conjugate (isotype control)

20005-12-HP 100 ug
EUR 202

Rat IgG2a-R-PE-Cy5.5 conjugate (isotype control)

20005-12-PC5 25 tests
EUR 213

Rat IgG2a-R-PE conjugate (isotype control)

20005-12-PE 25 tests
EUR 202

Rat IgG2b unconjugated (isotype control)

20005-13 100 ug
EUR 164

Rat IgG2b-Biotin conjugate (isotype control)

20005-13-B 100 ug
EUR 202

Rat IgG2b-FITC conjugate (isotype control)

20005-13-F 100 ug
EUR 225

Rat IgG2b-HRP conjugate (isotype control)

20005-13-HP 100 ug
EUR 202

Rat IgG2b-R-PE-Cy5.5 conjugate (isotype control)

20005-13-PC5 25 tests
EUR 213

Rat IgG2b-R-PE conjugate (isotype control)

20005-13-PE 25 tests
EUR 202

Rat IgG2c-Biotin conjugate (isotype control)

20005-14-B 100 ug
EUR 225

Rat IgG2c-FITC conjugate (isotype control)

20005-14-F 100 ug
EUR 225

Rat IgG2c-HRP conjugate (isotype control)

20005-14-HP 100 ug
EUR 225

Rat IgG2c-R-PE conjugate (isotype control)

20005-14-PE 50 tests
EUR 250

Rat IgG2c unonjugated (isotype control)

20005-14-UL 100 ug
EUR 164

Rat IgM (non-immune), purified (isotype control)

20005-2-1 0.1 mg
EUR 164

Rat IgM-Biotin conjugate (isotype control)

20005-21-B 100 ug
EUR 225

Rat IgM-FITC conjugate (isotype control)

20005-21-F 100 ug
EUR 225

Rat IgM-HRP conjugate (isotype control)

20005-21-HP 100 ug
EUR 225

Rat IgM-R-PE conjugate (isotype control)

20005-21-PE 25 tests
EUR 202

Rat IgA (non-immune), purified (isotype control)

20005-3-1 25 ug
EUR 225

Rat IgG, purified (Isotype control)

20005-5 5 mg
EUR 286

Rat IgG-Agarose conjugate(aff matrix)

20005-AS-1 0.5 ml
EUR 164

Rat IgG-Biotin conjugate (isotype control) (Isotype control)

20005-B 100 ug
EUR 164

Rat IgG-FITC conjugate (isotype control) (Isotype control)

20005-F 100 ug
EUR 164

Rat IgG-HRP conjugate (isotype control) (Isotype control)

20005-HP 100 ug
EUR 164

Rat IgG-PE conjugate (isotype control) (Isotype control)

20005-PE 25 tests
EUR 202

FluoroQuest™ Fluorescence Signal Enhancing Solution

20006 5 mL
EUR 132
  • R-phrase: R20, R21, R68
  • H-Phrase: H303, H313, H340
  • Symbol for dangerous compounds: T
  • UNSPEC Code: 12352200

Sheep IgG, purified (isotype control)

20006-1 1 mg
EUR 141

Sheep IgG-Biotin Conjugate (isotype control, non-immune), purified

20006-1-B 0.5 mg
EUR 202

Sheep IgG-FITC Conjugate (isotype control, non-immune), purified

20006-1-F 0.5 mg
EUR 202

Sheep IgG-HRP Conjugate (isotype control, non-immune), purified

20006-1-HP 0.5 mg
EUR 202

Sheep IgM purified (isotype control)

20006-2 1 mg
EUR 347

Sheep IgM-Biotin Conjugate (non-immune) control, purified

20006-2-B 0.1 mg
EUR 225

Sheep IgA purified (isotype control)

20006-3 100 ug
EUR 286

Sheep IgG Fc-Biotin Conjugate (isotype control, non-immune), purified

20006-4-B 0.5 mg
EUR 202

Sheep IgG Fc-FITC Conjugate (isotype control, non-immune), purified

20006-4-F 0.5 mg
EUR 202

Sheep IgG Fc-HRP Conjugate (isotype control, non-immune), purified

20006-4-HP 0.5 mg
EUR 202

Sheep IgG Fc unlabeled (isotype control, non-immune), purified

20006-4-UL 0.5 mg
EUR 202

Human IgG, purified (serum, non-immune, isotype control)

20007-1-1 1 mg
EUR 141

Human IgG, purified (serum, non-immune, isotype control)

20007-1-100 100 mg
EUR 895

Human IgG, purified (serum, non-immune, isotype control)

20007-1-25 25 mg
EUR 651

Human IgG, purified (serum, non-immune, isotype control)

20007-1-5 5 mg
EUR 286

Human IgG-Biotin conjugate (isotype control, non-immune), purified

20007-1-B 0.5 mg
EUR 225

Human IgG (>98%, non-immune, control, Liquid @ 10 mg/ml, azide free, bulk size)

20007-1-BL-1 10 ml Ask for price

Human IgG (>98%, non-immune, control, powder, azide free, bulk size)

20007-1-BP-1 1 g
EUR 651

Human IgG (>98%, non-immune, control, powder, azide free, bulk size)

20007-1-BP-10 10 g
EUR 4313

Human IgG-FITC conjugate (isotype control, non-immune), purified

20007-1-F 0.5 mg
EUR 225

Human IgG Fab fragment, purified

20007-1-FAB 1 mg
EUR 202

Human IgG Fab fragment-Biotin Conjugate, purified

20007-1-FAB-B 0.1 mg
EUR 202

Human IgG Fab fragment-FITC Conjugate, purified

20007-1-FAB-F 0.1 mg
EUR 202

Human IgG Fab fragment-HRP Conjugate, purified

20007-1-FAB-HP 0.1 mg
EUR 202

Human IgG F(ab')2 fragment, purified

20007-1-FAB2 1 mg
EUR 202

Human IgG Fab2 fragment-Biotin Conjugate, purified

20007-1-FAB2-B 0.1 mg
EUR 202

Genetic analysis of youngsters with congenital ocular anomalies in three ecological areas of Nepal: a piece II of Nepal pediatric ocular diseases analysis

Background: Genetic eye diseases characterize a giant and heterogeneous group of childhood ocular morbidity. Explicit particular person diseases might set off quite a few structural anomalies and developmental choices.

Nepal Pediatric Ocular Sickness Analysis (NPODS) was a population-based epidemiological analysis carried out all through three ecological areas of Nepal to seek out out the prevalence and etiology of childhood ocular morbidity and blindness. In Half II of this analysis, genetic analysis was carried out for youths who’ve been found to have congenital ocular anomalies.

Methodology: It was a cross sectional descriptive analysis. An entire of 10,270 kids all through three completely totally different ecological areas in Nepal (Low lands, hills, and mountains) underwent ocular examinations in NPODS.

Out of 374 (3.6%) of youngsters with ocular abnormalities, 30 have been thought of congenital in nature. Centered genetic analysis, along with genotyping for genes specific to presenting phenotype, was carried out for 25 kids using serum samples.

Outcomes: Out of 25 kids, 18 had vital genetic outcomes. Analysis revealed one missense alteration G12411T of Zinc Finger Homeobox 4 (ZFHX4) gene in a single participant amongst 10 with congenital ptosis and one different missense variation T > C P. Y374 C of Signaling Receptor and Transporter Retinol 6 (STRA6) gene in a single participant amongst Three with microphthalmos.

Conclusion: The analysis is first of its type from Nepal and mutant genes have been distinctive to Nepalese Inhabitants. Further analysis of genetic parts is important to greater understand genetic affiliation with ocular diseases and conditions. This helps further in genetic counseling and probably gene treatment to forestall blindness from these conditions.

 

Subsequent era sequencing reveals a novel pathogenic variant within the ATMgene

Introduction: Ataxia telangiectasia (A-T) is a unusual autosomal recessive multisystemic sickness. Victims with the A-T syndrome present a broad spectrum of sickness phenotypes. The ATM (ataxia telangiectasia mutated) gene, the one causative gene for A-T.

Methodology: A affected particular person of Persian origin presenting with typical A-T was referred to our genetics center for specialised genetic counseling and testing. Centered next-generation sequencing (NGS) was utilized.

Sanger sequencing was used to substantiate the candidate variant. Modeling was carried out using the SWISS-MODEL server.Outcomes: A homozygous stop-gain variant c.829G > T (p.E277*) was found throughout the ATM gene. This variant was confirmed by Sanger sequencing and modeling of native development and truncated development was carried out.

Conclusion: To this point, just a few pathogenic variants of the ATM gene have been reported from the Iranian inhabitants. The discovering has implications in molecular diagnostic for A-T in Iran.

Familial dilated cardiomyopathy introduced on by a novel variant throughout the Lamin A/C gene: a case report

Background: Familial dilated cardiomyopathy (FDCM) is usually inherited as an autosomal dominant trait. The Lamin A/C (LMNA) gene variants have been acknowledged to be associated to DCM, conductive system issues, form 2 Emery-Dreifuss muscular dystrophy and quite a few different totally different issues. Proper right here, we reported a novel variant throughout the LMNA gene that’s more likely to be related to FDCM.

 

Case presentation: A 30-year-old youthful man was hospitalized for chest tightness, extreme fatigue, palpitation and impaired train tolerance. He had scientific traits along with cardiac dilatation, atrial tachyarrhythmia, excessive conductive system issues, and dyskinesia of every greater limbs and the neck. Genetic sequence analysis indicated that the affected particular person carried a novel c.1325 T>C heterozygous LMNA gene variant. Catheter ablation and cardiac resynchronization treatment with pacing carry out (CRT-P) have been carried out to take care of the arrhythmia.

 

Conclusion: The variant c.1325 T>C is a novel variant throughout the LMNA gene that has not been beforehand reported. Youthful victims with DCM, conductive system issues and skeletal myopathy should be alert to the potential for LMNA gene variant. Cardiac resynchronization treatment (CRT) may be an reasonably priced choice for affected particular person carrying a LMNA gene variant with third-degree atrioventricular block even when the left ventricular ejection fraction is preserved with the intention to cease the deterioration of cardiac carry out introduced on by correct ventricular pacing dependency.

 

 

Doxorubicin hydrochloride

ADC-P-014 unit Ask for price

Doxorubicin (hydrochloride)

HY-15142 100mg
EUR 147

Doxorubicin hydrochloride

GA4969-100MG 100 mg
EUR 181

Doxorubicin hydrochloride

GA4969-10MG 10 mg
EUR 78

Doxorubicin hydrochloride

GA4969-25MG 25 mg
EUR 98

Doxorubicin hydrochloride

GA4969-50MG 50 mg
EUR 126

Doxorubicin hydrochloride

TNC00267 20mg Ask for price

Doxorubicin hydrochloride USP

D005-10MG 10 mg
EUR 166

Doxorubicin hydrochloride USP

D005-25MG 25 mg
EUR 301

Doxorubicin Hydrochloride (Autophagy inducer)

SIH-390-10MG 10 mg
EUR 193
  • Doxorubicin Hydrochloride is used in a clinical setting for the treatment of a wide range of cancers, including lymphomas, leukemias, and solid tumors of the breast, pancreas, stomach, bladder, and ovaries. This drug intercalates into DNA and therefo
  • Show more
Description: The substance Doxorubicin Hydrochloride is a autophagy inducer. It is synthetically produced and has a purity of >98%. The pure substance is red solid which is soluble in water (50 mM)..

Doxorubicin Hydrochloride (Autophagy inducer)

SIH-390-50MG 50 mg
EUR 529
  • Doxorubicin Hydrochloride is used in a clinical setting for the treatment of a wide range of cancers, including lymphomas, leukemias, and solid tumors of the breast, pancreas, stomach, bladder, and ovaries. This drug intercalates into DNA and therefo
  • Show more
Description: The substance Doxorubicin Hydrochloride is a autophagy inducer. It is synthetically produced and has a purity of >98%. The pure substance is red solid which is soluble in water (50 mM)..

Erlotinib, Hydrochloride Salt

1588-100
EUR 169

Erlotinib, Hydrochloride Salt

1588-1000
EUR 398

Doxorubicin

D063-100MG 100 mg
EUR 1051

Doxorubicin

D063-25MG 25 mg
EUR 322

Doxorubicin

abx188695-1g 1 g
EUR 467
  • Shipped within 1-2 weeks.

Doxorubicin

ADC-P-013 unit Ask for price

Doxorubicin

A3966-10 10 mg
EUR 108
Description: Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture. [1] It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.

Doxorubicin

A3966-100 100 mg
EUR 235
Description: Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture. [1] It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.

Doxorubicin

A3966-25 25 mg
EUR 131
Description: Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture. [1] It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.

Doxorubicin

A3966-5.1 10 mM (in 1mL DMSO)
EUR 131
Description: Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture. [1] It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.

Doxorubicin

A3966-S Evaluation Sample
EUR 81
Description: Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture. [1] It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.

Doxorubicin

HY-15142A 100mg
EUR 215

Erlotinib, Hydrochloride Salt, >99%

BC026-101 1g
EUR 273

Erlotinib, Hydrochloride Salt, >99%

BC026-102 2g
EUR 388

Erlotinib, Hydrochloride Salt, >99%

BC026-105 5g
EUR 570

Doxorubicin HCl

20-abx184016
  • EUR 746.00
  • EUR 1483.00
  • 1 g
  • 5 g
  • Shipped within 1-2 weeks.

Adriamycin (Doxorubicin)

E1KS1208 10mg
EUR 409

Doxorubicin 10mM

TG4120 0.25ml
EUR 156

17-DMAG, Hydrochloride Salt, >98%

BC024-001 1mg
EUR 178

17-DMAG, Hydrochloride Salt, >98%

BC024-005 5mg
EUR 286

17-DMAG, Hydrochloride Salt, >98%

BC024-010 10mg
EUR 408

17-DMAG, Hydrochloride Salt, >98%

BC024-025 25mg Ask for price

17-DMAG, Hydrochloride Salt, >99%

BC024-100 100mg Ask for price

17-DMAG, Hydrochloride Salt, >99%

BC024-101 1g Ask for price

17-DMAG, Hydrochloride Salt, >99%

BC024-250 250mg Ask for price

OSU-03012, Hydrochloride Salt, >98%

BC061-005 5mg
EUR 313

OSU-03012, Hydrochloride Salt, >98%

BC061-025 25mg
EUR 529

Doxorubicin (Adriamycin) HCl

A1832-10 10 mg
EUR 125
Description: Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture. [1] It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.

Doxorubicin (Adriamycin) HCl

A1832-100 100 mg
EUR 467
Description: Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture. [1] It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.

Doxorubicin (Adriamycin) HCl

A1832-25 25 mg
EUR 189
Description: Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture. [1] It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.

Doxorubicin (Adriamycin) HCl

A1832-5.1 10 mM (in 1mL DMSO)
EUR 113
Description: Doxorubicin is a semi-synthesized anticancer agent derived from bacterial culture. [1] It is an anthracycline antibiotic. It is been widely used in blood cancers, solid tumors and sarcomas.

Doxorubicin HCl, 100mg

R2531-100mg
EUR 1300

Doxorubicin HCl, 10mg

R2531-10mg
EUR 197

Anti-EGFR-doxorubicin ADC

ADC-W-600 1mg Ask for price
Description: This ADC product is comprised of an anti-EGFR monoclonal antibody conjugated via a linker to a doxorubicin

Anti-CD22-DIBO-doxorubicin ADC

ADC-W-339 1mg Ask for price
Description: This ADC product is comprised of an anti-CD22 monoclonal antibody conjugated via a DIBO linker to a doxorubicin

Anti-TNFRSF8 (cAC10)-DIBO-doxorubicin ADC

ADC-W-406 1mg Ask for price
Description: This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (cAC10) conjugated via a DIBO linker to a doxorubicin

Anti-ERBB2 (Trastuzumab)-NGM-doxorubicin ADC

ADC-W-412 1mg Ask for price
Description: This ADC product is comprised of an anti-ERBB2 monoclonal antibody conjugated via a NGM linker to adoxorubicin

Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC

ADC-W-504 1mg Ask for price
Description: This ADC product is comprised of an anti-EGFR monoclonal antibody (cetuximab) conjugated via a SMCC linker to Doxorubicin

Anti-EpCAM (MOC31)-hydrazone-Doxorubicin ADC

ADC-W-581 1mg Ask for price
Description: This ADC product is comprised of an anti-EPCAM monoclonal antibody (MOC31) conjugated via a hydrazone linker to Doxorubicin

Anti-FUT3 (clone cBR96)-hydrazone-doxorubicin ADC

ADC-W-423 1mg Ask for price
Description: This ADC product is comprised of an anti-FUT3 monoclonal antibody (clone cBR96) conjugated via a hydrazone linker to adoxorubicin

Anti-CD70 (clone h1F6)-β-glucuronide-doxorubicin ADC

ADC-W-376 1mg Ask for price
Description: This ADC product is comprised of an anti-CD70 monoclonal antibody (clone h1F6) conjugated via a β-glucuronide linker to a doxorubicin

Bile salt

BB0225 25g
EUR 79.58
  • Product category: Biochemicals/Detergents/Surfactants

Anti-TNFRSF8 (cCA10)-β-glucuronide-doxorubicin propyloxazoline (DPO) ADC

ADC-W-353 1mg Ask for price
Description: This ADC product is comprised of an anti-TNFRSF8 monoclonal antibody (cCA10) conjugated via a β-glucuronide linker to a doxorubicin propyloxazoline (DPO)

Human HeLa (Cervix Adenocarcinoma) Cell Nuclear Extract - Doxorubicin Stimulated

HCL-2004 100ug
EUR 225

Human HeLa (Cervix Adenocarcinoma) Whole Cell Lysate - Doxorubicin Stimulated

HCL-2010 100ug
EUR 213

TAME Hydrochloride

2050-100
EUR 126

TAME Hydrochloride

2050-1000
EUR 479

TAME Hydrochloride

2050-500
EUR 338

Verapamil hydrochloride

2861-1G
EUR 131

Verapamil hydrochloride

2861-5G
EUR 327

Ticlopidine hydrochloride

2919-25
EUR 403

Ticlopidine hydrochloride

2919-5
EUR 153

EHNA hydrochloride

2265-25
EUR 283

EHNA hydrochloride

2265-5
EUR 115

AdipoRon hydrochloride

2572-25
EUR 588

AdipoRon hydrochloride

2572-5
EUR 185

Pargyline hydrochloride

2618-1000
EUR 175

Pargyline hydrochloride

2618-500
EUR 120

Clorgyline hydrochloride

2622-10
EUR 120

Clorgyline hydrochloride

2622-50
EUR 327

Clindamycin hydrochloride

2627-10
EUR 131

Clindamycin hydrochloride

2627-50
EUR 370

Loperamide hydrochloride

2683-1000
EUR 185

Loperamide hydrochloride

2683-500
EUR 131

Clonidine hydrochloride

2684-100
EUR 131

Clonidine hydrochloride

2684-500
EUR 359

Leelamine hydrochloride

2717-25
EUR 457

Leelamine hydrochloride

2717-5
EUR 153

SBE13 hydrochloride

2847-10
EUR 185

SBE13 hydrochloride

2847-50
EUR 588

Amodiaquine hydrochloride

A085-5G 5 g
EUR 55

Metformin, Hydrochloride

1691-5G
EUR 158

Irinotecan Hydrochloride

1752-250
EUR 387

Irinotecan Hydrochloride

1752-50
EUR 147

Epirubicin Hydrochloride

1753-25
EUR 457

Epirubicin Hydrochloride

1753-5
EUR 158

Gemcitabine Hydrochloride

1759-100
EUR 370

Gemcitabine Hydrochloride

1759-25
EUR 156

Amiodarone Hydrochloride

1828-100
EUR 126

Amiodarone Hydrochloride

1828-500
EUR 338

Phenformin hydrochloride

1889-100
EUR 115

Phenformin hydrochloride

1889-1000
EUR 359

Tomatidine hydrochloride

1893-25
EUR 137

Vancomycin Hydrochloride

B1507-1G
EUR 153

Vancomycin Hydrochloride

B1507-250
EUR 120

Vancomycin Hydrochloride

B1507-5G
EUR 262

Lincomycin Hydrochloride

B1524-1G
EUR 142

Lincomycin Hydrochloride

B1524-5G
EUR 403

Leave a Reply

Your email address will not be published. Required fields are marked *